This work suggests that tumor antigen-specific TIL, likely the CD8+ PD-1+ subset, have decreased replicative fitness during ex vivo expansion due to their exhausted nature, and are thus out-competed by less differentiated clonotypes that lack tumor-specificity. This evidence concerns the gene CD8A and neoplasm.